Holen Sie sich die Stockscreener-App
55.81
0.79%
0.44
Handel nachbörslich:
55.56
-0.25
-0.45%
Schlusskurs vom Vortag:
$55.37
Offen:
$55.81
24-Stunden-Volumen:
2.32M
Relative Volume:
0.88
Marktkapitalisierung:
$14.03B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$833.42M
KGV:
18.50
EPS:
3.0172
Netto-Cashflow:
$917.69M
1W Leistung:
+0.50%
1M Leistung:
+1.90%
6M Leistung:
+27.59%
1J Leistung:
+22.39%
1-Tages-Spanne:
$55.69
$56.73
1-Wochen-Bereich:
$54.20
$56.73
52-Wochen-Spanne:
$33.76
$57.57
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
55.81 | 13.92B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-11-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Exelixis Inc (EXEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exelixis Inc (EXEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Exelixis, Inc. Revenue Breakdown – BX:EX9 - TradingView
Exelixis Inc (EXEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exelixis Inc (EXEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Exelixis, Inc. Revenue Breakdown – LSX:936718 - TradingView
EXEL|Exelixis Inc|Price:55.370|Chg%:-0.280 - TradingKey
EXELIXIS INC EXELIXIS ORD SHS (0IJO.L) Q1 FY2026 earnings call transcript - Yahoo Finance
Exelixis Inc (EXEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
EXEL Maintained by Morgan Stanley -- Price Target Raised to $53 - GuruFocus
EXEL stock trades steadily as Exelixis leans on expanding oncology revenue - Ad-hoc-news.de
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 - BioSpace
What Happened at Exelixis (NASDAQ:EXEL) Before Results Date? - Kalkine Media
Exelixis to release Q2 2026 financial results on August 5 - scanx.trade
Lobbying Update: $560,000 of EXELIXIS INC. lobbying was just disclosed - Quiver Quantitative
Exelixis (EXEL) earnings expected to grow: Should you buy? - MSN
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
(EXEL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
What's Driving Exelixis' Recent Momentum and 2026 Outlook - Kavout | AI
Exelixis (EXEL) Stock May Be Undervalued Following FDA Review Uncertainty - simplywall.st
EXEL Maintained by Barclays -- Price Target Raised to $49 - GuruFocus
Analysts Conflicted on These Healthcare Names: Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Exelixis, Inc. (EXEL) hit a 52-week high, can the run continue? - MSN
Daily Brief Industrials: Archion, Baycurrent, easyJet PLC, Hanjin KAL Corp, World-Link Logistics (Asia), Genneia, Robotechnik Intelligent Te-A, Shenzhen Megmeet Electrical , Exelixis Inc, Rush Enterprises Inc Cl A and more - Smartkarma
Daily Brief Health Care: Apnimed, Cigna Group, Exelixis Inc, Scribe Therapeutics, CSPC Pharmaceutical and more - Smartkarma
Daily Brief Financials: SBI Funds Management Ltd, Choice International, Kotak Mahindra Bank, Exelixis Inc, Bank Mandiri Persero, Ryan Specialty Holdings and more - Smartkarma
symbol__ Stock Quote Price and Forecast - CNN
EXEL Maintained by Wells Fargo -- Price Target Raised to $49.00 - GuruFocus
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth In The Oncology Biotech Space - DirectorsTalk Interviews
Is Exelixis (EXEL) Expensive After Its Recent Rally Or Still Undervalued? - Yahoo Finance
Exelixis (EXEL) Stock Trades At A Discount After Its 236% Run - Yahoo Finance
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth? - Yahoo Finance
Exelixis Announces Zanzalintinib in Combinati - Moomoo
Exelixis: STELLAR-303 Results Mixed, STELLAR-304 Success Likely (NASDAQ:EXEL) - Seeking Alpha
Is Exelixis, Inc. (EXEL) Among the Best Under-the-Radar Stocks to Invest In? - Yahoo Finance
Handa, Intas Face Patent Suits Over Exelixis Cancer Drug - Law360
Exelixis focuses on oncology pipeline as Nasdaq-listed biotech pursues growth - ad-hoc-news.de
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June - AOL.com
Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists - Investor's Business Daily
EXEL Maintained by RBC Capital -- Price Target Raised to $46.00 - GuruFocus
Exelixis Inc stock hits all-time high at 56.22 USD - Investing.com
Exelixis Inc stock hits all-time high at 56.22 USD By Investing.com - Investing.com Nigeria
Truist Financial Maintains Exelixis(EXEL.US) With Hold Rating, Raises Target Price to $56 - Moomoo
RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating - marketscreener.com
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Strong Revenue Growth and High Analyst Interest - DirectorsTalk Interviews
Zanzalintinib Trial Outcomes And Index Exit Might Change The Case For Investing In Exelixis (EXEL) - simplywall.st
ETFs Investing in Exelixis, Inc. Stocks - TradingView
Price to sales forward of Exelixis, Inc. – NASDAQ:EXEL - TradingView
Exelixis, Inc. (EXEL) Stock Price Today - CoinMarketCap
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):